title: Lesion of the anteroventral third ventricle (AV3V) reduces hypothalamic activation and hypophyseal hormone secretion induced by lipopolysaccharide in rats.
abstract: This study examined whether electrolytic ablation of the periventricular anteroventral third ventricle (AV3V) region would affect the hypothalamic activation and the increase of hypophysial hormone secretion induced by systemic injection of lipopolysaccharide (LPS) in rats. LPS significantly increased the number of cells showing Fos immunoreactivity in the paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus (P<0.05) and also increased plasma levels of vasopressin, oxytocin, adrenocorticotropin and corticosterone (P<0.05). AV3V lesion significantly reduced LPS-induced Fos immunoreactivity (P<0.05) and vasopressin and oxytocin secretion (P<0.05). Elevations in adrenocorticotropin but not in plasma corticosterone after LPS were affected by prior AV3V lesions. These findings demonstrate that LPS-induced Fos expression in the PVN and SON, and hypophysial hormone secretion is dependent on the integrity of the AV3V region.
authors.affiliation: Departamento de Fisiologia da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
authors.forename: Beatriz
authors.initials: B
authors.lastname: de Carvalho Borges
authors.forename: Evelin Capellari
authors.initials: EC
authors.lastname: Carnio
authors.forename: Lucila Leico Kagohara
authors.initials: LL
authors.lastname: Elias
authors.forename: José
authors.initials: J
authors.lastname: Antunes-Rodrigues
authors.forename: Luiz Guilherme Siqueira
authors.initials: LG
authors.lastname: Branco
authors.forename: Maria José Alves
authors.initials: MJ
authors.lastname: da Rocha
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D002320:Cardiovascular Physiological Phenomena; D004195:Disease Models, Animal; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism*; D007031:Hypothalamus / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology*; D018836:Inflammation Mediators / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D010121:Oxytocin / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism; D010907:Pituitary Hormones / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012772:Shock, Septic / Q000378:metabolism / Q000503:physiopathology; D013312:Stress, Physiological / Q000378:metabolism / Q000503:physiopathology; D013495:Supraoptic Nucleus / Q000187:drug effects / Q000378:metabolism; D020542:Third Ventricle / Q000033:anatomy & histology / Q000502:physiology*; D014667:Vasopressins / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000502:physiology
chemical_list: D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D010907:Pituitary Hormones; D016760:Proto-Oncogene Proteins c-fos; D014667:Vasopressins; D010121:Oxytocin; D000324:Adrenocorticotropic Hormone